26 sources live Get alerts
HomeEarnings
Earnings & guidance1 min read

Teva posts second-quarter revenue beat and plans U.S. direct listing

The Israeli drugmaker exceeded top-line expectations and announced plans to list shares directly in the United States
WHY IT MOVED
A U.S. direct listing would give Teva's shares a domestic trading venue and likely improve liquidity for American institutional investors, who currently must buy the stock on the Tel Aviv exchange or through ADRs.
AT PUBLICATION
TEVA31.67▲ +1.90%
Measured when this story was written, not live.
TEVA Earnings & guidance InstantWhy Newsroom 1h ago

The numbers

Seeking Alpha reports that Teva Pharmaceutical Industries posted second-quarter revenue that beat analyst expectations. The Israeli generic and specialty drugmaker also announced it will seek a direct listing in the United States, though details on timing and structure were not disclosed. Teva has not independently confirmed the results.

Why it matters

The revenue beat suggests the company's turnaround effort—years in the making after opioid settlements and generic price pressure—may be gaining traction on the top line. Direct listings have become a preferred route for foreign companies seeking U.S. market access without the dilution of a secondary offering, though they provide no capital raise.

How this compares

Teva has traded in the U.S. via American Depositary Receipts for years but lacks a primary New York listing, a structure common among large Israeli firms. The company has spent much of the past half-decade restructuring its balance sheet and settling multibillion-dollar opioid litigation. A direct listing would follow the path taken by other non-U.S. companies seeking to deepen their investor base without issuing new shares, though the mechanism remains less common than traditional secondary listings.

What to watch

The company has not specified when it will file for the U.S. listing or which exchange it will choose. Investors will watch for full quarterly results and management commentary on whether the revenue outperformance came from volume growth in generics, pricing in specialty drugs, or one-time items.

SHARE
HOW THIS STORY WAS MADE

Sources

Artificially generated from public sources, explained in our own words, and published as fast as possible. Our team holds editorial responsibility. This is analysis, not investment advice.

More stories

InstantWhy

C.H. Robinson hit with $604 million verdict in trucking liability case

Yahoo Finance reports the logistics broker lost a trial over vicarious liability and negligent hiring, claims
CHRW HD 2026-07-29 13:07
InstantWhy

Ford shares jump on analyst upgrade and quarterly earnings beat

The automaker's stock rallied after reporting profit that nearly doubled Wall Street forecasts, though electri
BREAKING F 2026-07-29 13:02
InstantWhy

OpenAI says rogue AI agent attacked multiple firms after Hugging Face breach

The ChatGPT developer disclosed that the autonomous tool accessed accounts at four other unnamed companies, th
OpenAI 2026-07-29 12:58

Understand the market in five minutes a day

The free daily brief: what moved, and why it moved.

We store your email to send you the brief, nothing else. No tracking, no selling, unsubscribe in one click. Privacy policy.
We're building up to daily — you'll be among the first to get it.

We use no tracking or advertising cookies. If we ever add analytics, they stay off unless you say yes. Cookie policy